SEATTLE and COPENHAGEN, Denmark, Sept. 10, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, announced today it has hired Mark W. Sawicki, Ph.D., to serve as the Company's new Vice President of Global Business Development. Dr. Sawicki will be focused on business development, sales management, and the integration and alignment of the Company's global sales and marketing team.
"Mark brings broad experience and documented success in the pharmaceutical/biotechnology industry," said Gustavo Mahler, Chief Operations Officer of CMC Biologics. "His results-oriented approach and business acumen will play a pivotal role in extending our track record of innovation, while helping us grow profitability and take full advantage of the global contract manufacturing market opportunities ahead. In his role as Vice President, Global Business Development, he will be responsible for realizing the full potential of the sales and marketing team and provide leadership to this exciting phase of CMC Biologics' growth".
"CMC Biologics is very well respected, has a growing global customer base, offers world-class analytical, process development and manufacturing services, and has recently introduced new innovative services and technologies to its offering, giving the company a very attractive growth potential." said Dr. Sawicki. "I see a bright future for CMC Biologics and am eager to be part of the experienced and dedicated team and the challenges ahead."
Dr. Sawicki brings 10 years of business development and sales management experience, consistently delivering on corporate revenue and market share goals in the pharmaceutical/biotechnology industry. Prior, Sawicki was Vice President, Business Development-Europe for Albany Molecular Research, Inc. responsible for business development and sales activity in the European theater, as well as global key account management strategy. He consistently increased sales revenue at rates far outpacing industry standards from the EU Theater and prior, the US, and developed market analysis models for AMRI to determine market factors to proactively envisage future geographic/business shifts and trends. He holds Ph.D. and B.S. degrees in biochemistry from State University of New York at Buffalo; is a member of the Editorial Advisory of Pharmaceutical Outsourcing; and has more than a dozen publications in drug discovery and biochemistry.
About CMC Biologics
CMC Biologics is a global contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world from its facilities in Europe and the USA. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. CMC Biologics is located in Copenhagen, Denmark; Seattle, Washington; and Berkeley, California. More detailed information can be found at www.cmcbiologics.com.
|SOURCE CMC Biologics|
Copyright©2012 PR Newswire.
All rights reserved